Market news

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (“Baird Medical” or the “Company”) (Nasdaq: BDMD), a global medical technology company focused on the development and commercialization of minimally invasive treatment solutions, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. H.C. Wainwright 28th Annual Global Investment ConferenceDate: Wednesday, September 16, 2026Time: 11:30 a.m.

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (“Baird Medical” or the “Company”) (Nasdaq: BDMD)...

By Tom Kerr, CFA NASDAQ: BDMD READ THE FULL BDMD RESEARCH REPORT Interim Financial Results On September 3, 2026, Baird Medical (NASDAQ: BDMD) released financial results for the 6-month period ending June 30, 2026, which showed strong revenue growth from non-China regions. Revenue grew 24.6% to approximately $9.9 million in the 1st half of 2026, compared with $8.0 million in the prior-year period.

Revenue increase driven by significant growth in the United States and other strategic marketsNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), today announced preliminary unaudited financial results for the six months ended June 30, 2026. Revenue for the first half of 2026 was approximately $9.9 million, an increase of 24.6% over $8.0 million reported for the six months ended June 30, 2025. The increase in reve

Registrations cover the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation NeedleNEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company’s commercial activities in the country.

By Tom Kerr, CFA NASDAQ: BDMD READ THE FULL BDMD RESEARCH REPORT Founded in 2012 in Guangzhou, China, Baird Medical Investment Holdings (NASDAQ: BDMD) is a leading microwave ablation ("MWA") medical device manufacturer and provider for the minimally invasive treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Baird Medical was the

Baird Medical and Alpmed Le (Lynn) Zhang, Vice President of Baird Medical Group, and Jiliang (William) Zhang, Vice President of Alpmed, at the signing of the companies’ strategic partnership agreement Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technologyCollaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, includ